These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16368455)

  • 1. Evaluation of the cost-effectiveness of sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom.
    McEwan P; Baboolal K; Conway P; Currie CJ
    Clin Ther; 2005 Nov; 27(11):1834-46. PubMed ID: 16368455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes.
    Orme ME; Jurewicz WA; Kumar N; McKechnie TL
    Pharmacoeconomics; 2003; 21(17):1263-76. PubMed ID: 14986738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK.
    McEwan P; Dixon S; Baboolal K; Conway P; Currie CJ
    Pharmacoeconomics; 2006; 24(1):67-79. PubMed ID: 16445304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost-effectiveness analyses.
    Lazzaro C; McKechnie T; McKenna M
    J Nephrol; 2002; 15(5):580-8. PubMed ID: 12455727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of sirolimus therapy with early cyclosporin withdrawal vs. long-term cyclosporin therapy in Australia.
    Gordois A; Nobes M; Toohey M; Russ G
    Clin Transplant; 2006; 20(4):526-36. PubMed ID: 16842533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach.
    Jürgensen JS; Arns W; Hass B
    Eur J Health Econ; 2010 Feb; 11(1):15-25. PubMed ID: 19296139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2016 Oct; 19(10):995-1002. PubMed ID: 27172118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2015; 18(12):1050-9. PubMed ID: 26201252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2014 Jul; 17(7):520-6. PubMed ID: 24754700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of modern mTOR inhibitor based immunosuppression compared to the standard of care after renal transplantation in Germany.
    Jürgensen JS; Ikenberg R; Greiner RA; Hösel V
    Eur J Health Econ; 2015 May; 16(4):377-90. PubMed ID: 24728542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J; Kahan BD
    Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Projecting long-term graft and patient survival after transplantation.
    Levy AR; Briggs AH; Johnston K; MacLean JR; Yuan Y; L'Italien GJ; Kalsekar A; Schnitzler MA
    Value Health; 2014 Mar; 17(2):254-60. PubMed ID: 24636384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost evaluation of basiliximab treatment for renal transplant patients in Japan.
    Hasegawa T; Imai H; Miki S
    Pharmacoeconomics; 2003; 21(11):791-806. PubMed ID: 12859220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen.
    Irish W; Sherrill B; Brennan DC; Lowell J; Schnitzler M
    Transplantation; 2003 Dec; 76(12):1686-90. PubMed ID: 14688516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of sirolimus-based immunosuppressive regimens in kidney graft recipients.
    Niemczyk M; Nowak M; Pilecki T; Wyzgał J; Ziółkowski J; Zygier D; Paczek L
    Transplant Proc; 2006; 38(1):74-7. PubMed ID: 16504668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive agents in adult kidney transplantation in the National Health Service: a model-based economic evaluation.
    Snowsill TM; Moore J; Mujica Mota RE; Peters JL; Jones-Hughes TL; Huxley NJ; Coelho HF; Haasova M; Cooper C; Lowe JA; Varley-Campbell JL; Crathorne L; Allwood MJ; Anderson R
    Nephrol Dial Transplant; 2017 Jul; 32(7):1251-1259. PubMed ID: 28873970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus Versus Cyclosporine as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation.
    Liu JY; You RX; Guo M; Zeng L; Zhou P; Zhu L; Xu G; Li J; Liu D
    Am J Ther; 2016; 23(3):e810-24. PubMed ID: 25299636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.